» Articles » PMID: 17921436

Sterol-dependent Regulation of Proprotein Convertase Subtilisin/kexin Type 9 Expression by Sterol-regulatory Element Binding Protein-2

Overview
Journal J Lipid Res
Publisher Elsevier
Specialty Biochemistry
Date 2007 Oct 9
PMID 17921436
Citations 137
Authors
Affiliations
Soon will be listed here.
Abstract

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a member of the subtilases that promotes the internalization and degradation of LDL receptor in liver and thereby controls the level of LDL cholesterol in plasma. Here, we show that the expression of PCSK9 in HepG2 cells is completely dependent on the absence or presence of sterols. The minimal promoter region of the PCSK9 gene contains a sterol-regulatory element (SRE), which makes the transcription of PCSK9 dependent on sterols. Expression of nuclear forms of sterol-regulatory element binding protein-1 (SREBP-1) and SREBP-2 dramatically increased the promoter activity of PCSK9. In vitro-translated nuclear forms of SREBPs showed interactions with SRE, whereas mutations in SRE abolished their binding. In vivo studies in mice showed that Pcsk9 protein and mRNA were decreased significantly by fasting and increased by refeeding. However, supplementation with 2% cholesterol in the diet prevented the increase in Pcsk9. The amounts of Pcsk9 mRNA in livers of refed mice showed correlated regulation by the changes in the nuclear form of Srebp-2. In summary, it is suggested that the expression of PCSK9 is regulated by sterol at the transcriptional level in HepG2 cells and that both SREBP-1 and SREBP-2 can transcriptionally activate PCSK9 via SRE in its proximal promoter region in vitro. However, in vivo, it is suggested that the sterol-dependent regulation of PCSK9 is mediated predominantly by SREBP-2.

Citing Articles

"Inclisiran: Early LDL-C target achievement in a real-life population".

Briani F, Bagli M, Venturi G, Bacchion F, Mugnolo A Atheroscler Plus. 2025; 59:54-58.

PMID: 39996142 PMC: 11848444. DOI: 10.1016/j.athplu.2025.01.001.


Lindl. alkaloids improve lipid metabolism by increasing LDL uptake through regulation of the LXRα/IDOL/LDLR pathway and inhibition of PCSK9 expression in HepG2 cells.

Sun J, Liu H, Zhu Y, Zhang W, Shi J, Wu Q Exp Ther Med. 2025; 29(3):46.

PMID: 39885913 PMC: 11775753. DOI: 10.3892/etm.2025.12796.


PCSK9 in T-cell function and the immune response.

Wang Y, Fang X, Liu J, Lv X, Lu K, Lu Y Biomark Res. 2024; 12(1):163.

PMID: 39736777 PMC: 11687167. DOI: 10.1186/s40364-024-00712-8.


MiR-99a-5p up-regulates LDLR and functionally enhances LDL-C uptake via suppressing PCSK9 expression in human hepatocytes.

Chen X, Liu Y, Zhou Q, Zhang C, Wang W, Xu M Front Genet. 2024; 15:1469094.

PMID: 39628814 PMC: 11611869. DOI: 10.3389/fgene.2024.1469094.


New epigenome players in the regulation of PCSK9-H3K4me3 and H3K9ac alterations by statin in hypercholesterolemia.

Duddu S, Katakia Y, Chakrabarti R, Sharma P, Shukla P J Lipid Res. 2024; 66(1):100699.

PMID: 39566851 PMC: 11699316. DOI: 10.1016/j.jlr.2024.100699.